Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Medicinova Inc (MNOV)

Medicinova Inc (MNOV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 82,397
  • Shares Outstanding, K 49,046
  • Annual Sales, $ 1,000 K
  • Annual Income, $ -8,570 K
  • EBIT $ -10 M
  • EBITDA $ -10 M
  • 60-Month Beta 0.77
  • Price/Sales 81.42
  • Price/Cash Flow N/A
  • Price/Book 1.42

Options Overview Details

View History
  • Implied Volatility 209.73% ( +37.61%)
  • Historical Volatility 56.98%
  • IV Percentile 70%
  • IV Rank 31.62%
  • IV High 619.24% on 06/04/24
  • IV Low 20.38% on 10/15/24
  • Put/Call Vol Ratio 0.20
  • Today's Volume 6
  • Volume Avg (30-Day) 24
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 353
  • Open Int (30-Day) 354

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.01
  • Growth Rate Est. (year over year) -500.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5700 +7.01%
on 10/28/24
2.0475 -17.95%
on 10/07/24
-0.3000 (-15.15%)
since 10/04/24
3-Month
1.1200 +50.00%
on 08/12/24
2.1500 -21.86%
on 09/04/24
+0.4695 (+38.79%)
since 08/05/24
52-Week
1.1200 +50.00%
on 08/12/24
2.1600 -22.22%
on 11/20/23
-0.2200 (-11.58%)
since 11/03/23

Most Recent Stories

More News
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

MNOV : 1.6000 (-4.76%)
MediciNova: Q1 Earnings Snapshot

MediciNova: Q1 Earnings Snapshot

MNOV : 1.6000 (-4.76%)
MediciNova: Q3 Earnings Snapshot

MediciNova: Q3 Earnings Snapshot

MNOV : 1.6000 (-4.76%)
MediciNova: Q2 Earnings Snapshot

MediciNova: Q2 Earnings Snapshot

MNOV : 1.6000 (-4.76%)
MediciNova: Q1 Earnings Snapshot

MediciNova: Q1 Earnings Snapshot

MNOV : 1.6000 (-4.76%)
MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

LA JOLLA, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and...

MNOV : 1.6000 (-4.76%)
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea

LA JOLLA, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and...

MNOV : 1.6000 (-4.76%)
MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

LA JOLLA, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and...

MNOV : 1.6000 (-4.76%)
MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)

LA JOLLA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and...

MNOV : 1.6000 (-4.76%)
MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

LA JOLLA, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and...

MNOV : 1.6000 (-4.76%)

Business Summary

MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanesepharmaceutical companies,...

See More

Key Turning Points

3rd Resistance Point 1.8375
2nd Resistance Point 1.7820
1st Resistance Point 1.7310
Last Price 1.6000
1st Support Level 1.6245
2nd Support Level 1.5690
3rd Support Level 1.5180

See More

52-Week High 2.1600
Fibonacci 61.8% 1.7627
Fibonacci 50% 1.6400
Last Price 1.6000
Fibonacci 38.2% 1.5173
52-Week Low 1.1200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar